TY - JOUR
T1 - Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
AU - Siddiqui, Maria Tariq
AU - Price, Allyson
AU - Ferrajoli, Alessandra
AU - Borthakur, Gautam
N1 - Publisher Copyright:
© 2021
PY - 2021/1
Y1 - 2021/1
N2 - B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years.
AB - B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years.
KW - B cell prolymphocytic leukemia
KW - Deletion 17p
KW - Ibrutinib
KW - TP53
KW - Venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85116898382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116898382&partnerID=8YFLogxK
U2 - 10.1016/j.lrr.2021.100266
DO - 10.1016/j.lrr.2021.100266
M3 - Article
C2 - 34692401
AN - SCOPUS:85116898382
SN - 2213-0489
VL - 16
JO - Leukemia Research Reports
JF - Leukemia Research Reports
M1 - 100266
ER -